Biodesix, Inc. cash flow to debt ratio of -31.94% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Biodesix, Inc.'s free cash flow has increased -54.37% from $-51.88M last year to $-23.67M, signaling increasing performance

Biodesix, Inc.'s debt to equity ratio is 7.84, which means that the company's assets are unhealthy financed, signaling financial risk. READ MORE: A ratio over 0.60 means the company finances its assets with debt, signaling financial risk. If ratio is negative, the company spent its own equity and risks bankruptcy

Biodesix, Inc.'s debt has increased relative to shareholder equity from 2.97 last year to 7.84 today, signaling weakened financials

Biodesix, Inc. has negative EBITDA, making leverage ratio unreliable

Biodesix, Inc.'s interest coverage ratio is -3.11, which means that the company struggles to meet interest obligations, signaling financial risk.

Biodesix, Inc.'s profit margin has increased (-44.75%) in the last year from -60.19% to -33.26%, signaling increasing performance

Biodesix, Inc.'s short-term assets of $32.52M exceed its short-term liabilities of $17.44M

Biodesix, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Biodesix, Inc.'s return on equity of -2.10K%, is lower than 15.00%, indicating bad performance

Biodesix, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Biodesix, Inc. had positive net income in only 0.00 out of 5 years, indicating unstable earnings

Biodesix, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Biodesix, Inc. has negative free cash flow, indicating cash burn

Biodesix, Inc.'s yearly earnings has increased -17.86% since last year from $-42.93M to $-35.27M, signaling increasing performance

Biodesix, Inc.'s yearly revenue has increased 24.08% since last year from $71.32M to $88.50M, signaling increasing performance

ROIC -30.51% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Biodesix, Inc.'s 3-year revenue CAGR of 32.31% is positive, indicating growing revenue over the past 3 years

Biodesix, Inc. had revenue growth in 4.00 out of 5 years, indicating consistent revenue performance

Biodesix, Inc. had positive ROE in only 0.00 out of 5 years, indicating inconsistent returns on equity

Biodesix, Inc. has insufficient data to evaluate this check.

Biodesix, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Biodesix, Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Biodesix, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Biodesix, Inc. has insufficient data to evaluate this check.

Biodesix, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Biodesix, Inc. has negative shareholder equity; price-to-book is not meaningful and the check fails

Biodesix, Inc. has a price-to-sales ratio of 1.98x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue